Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9469)	11/12/2003 12:07:00 PM
From: Biomaven	Respond to of 52153

<MYGN continued> The mice used in this experiment were transgenic Tg2576 mice that produce the human amyloid precursor protein and demonstrate a progressive, age-related deposition of beta-amyloid plaques, modeling human Alzheimer's disease. In the Morris water maze, mice learn the position of a partially submerged platform within a circular water tank using spatial cues around the tank. In several trials per day, they are released from different starting points close to the wall of the tank and must swim until they find their way to the platform. After a few days of training, the time to reach the platform will decrease because the mouse learns the location of the platform relative to the spatial cues. The platform is then removed from the tank and the animal's spatial learning is evaluated by the length of time it spends searching the appropriate quadrant of the tank, where the platform was located. A mouse with difficulty learning or poor memory would swim randomly around the tank, and on average, would spend 25% of its time in each quadrant. Untreated control animals in this experiment spent approximately 30% of their time in the correct quadrant, indicating little ability to learn and remember spatial cues. Ibuprofen had no significant effect on learning, even at very high doses, compared with untreated control mice in this study. However, R-flurbiprofen treated mice spent approximately 60% of their total time, more than twice as much as the controls, in the correct quadrant, indicating that they still recalled its location. "This is a truly remarkable result for the R-flurbiprofen treated mice in this study," said Todd Golde, Ph.D., Chairman of Neuroscience at Mayo Clinic. "Our experience is that the water maze is a difficult task for mice generally, and well-trained normal healthy mice rarely spend more than 50% of their time in the correct quadrant. This group of treated mice performed exceptionally well, at 60%, with no apparent loss of cognition as measured in this study." In addition to improving spatial learning, mouse pathology was examined to determine whether a difference could be detected in the accumulation of amyloid plaques in the brain, between the drug-treated groups and controls. Initial analysis indicated that there was a robust reduction in the amount of insoluble amyloid levels in the brains of the R-flurbiprofen treated mice. Myriad is developing R-flurbiprofen (MPC-7869) for the treatment of Alzheimer's disease, and has a Phase II human clinical trial ongoing in the United Kingdom and Canada.